Literature DB >> 34224208

Global incidence, prevalence and features of primary sclerosing cholangitis: A systematic review and meta-analysis.

Tej I Mehta1, Simcha Weissman2, Brian M Fung3, John Sotiriadis4, Keith D Lindor5, James H Tabibian6,7.   

Abstract

BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an idiopathic, cholestatic liver disease with a diverse range of clinical manifestations. Inter-regional data on PSC are variable, but its global geoepidemiology has not been well-studied. We aimed to examine the worldwide incidence, prevalence and features of PSC and PSC-inflammatory bowel disease (PSC-IBD).
METHODS: A systematic search of multiple databases was conducted to identify all original, full-text studies until December 2020 with data regarding the incidence rate (IR) and/or prevalence of PSC. Outcomes were PSC IR, prevalence, features and IBD concurrence. Additionally, a meta-analysis of PSC IR was performed. The study was registered in PROSPERO (CRD42021224550).
RESULTS: Of the 1003 studies identified, 17 studies spanning three continents were included. PSC IR was 0.60 per 100 000 person-years (PY) (95% confidence interval: 0.37-0.88 per 100 000 PY). In pooled subgroup analysis for studies conducted in Europe and North America, PSC IR was 0.62 and 0.53 per 100 000 PY, respectively. PSC prevalence ranged 0-31.7 per 100 000 persons, with notable inter-regional differences. Mean age at PSC diagnosis was bimodally distributed, with relative peaks at 15 and 35 years. Mean concurrence of IBD with PSC was 50%, with 76% having ulcerative colitis, 17% Crohn's disease and 8% indeterminate/unspecified IBD.
CONCLUSION: While considerable heterogeneity exists in the geoepidemiology of PSC, overall, the classical dogmata of male predilection, bimodal distribution of mean age and high PSC-IBD concurrence appear to hold true. Despite a seemingly stable IR over time, further studies are needed to better understand the geoepidemiology of PSC.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  autoimmune; incidence; inflammatory bowel disease; prevalence

Year:  2021        PMID: 34224208     DOI: 10.1111/liv.15007

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  6 in total

1.  May Previous Hepatitis B Virus Infection Be Involved in Etiology and Pathogenesis of Autoimmune Liver Diseases?

Authors:  Sergey Batskikh; Sergey Morozov; Elena Vinnitskaya; Evgeniya Sbikina; Zanna Borunova; Alexey Dorofeev; Yulia Sandler; Kirill Saliev; Dmitry Kostyushev; Sergey Brezgin; Anastasiya Kostyusheva; Vladimir Chulanov
Journal:  Adv Ther       Date:  2021-11-11       Impact factor: 3.845

Review 2.  Primary sclerosing cholangitis: review for radiologists.

Authors:  Matthew A Morgan; Rachita Khot; Karthik M Sundaram; Daniel R Ludwig; Rashmi T Nair; Pardeep K Mittal; Dhakshina M Ganeshan; Sudhakar K Venkatesh
Journal:  Abdom Radiol (NY)       Date:  2022-09-05

3.  Is primary sclerosing cholangitis with inflammatory bowel disease different between patients in the East and West?

Authors:  Yong Eun Park
Journal:  Intest Res       Date:  2022-04-29

4.  Clinical Features and Outcomes of Primary Sclerosing Cholangitis in the Highly Admixed Brazilian Population.

Authors:  Mateus Jorge Nardelli; Paulo Lisboa Bittencourt; Guilherme Grossi Lopes Cançado; Luciana Costa Faria; Cristiane Alves Villela-Nogueira; Vivian Rotman; Eliabe Silva de Abreu; Fernanda Maria Farage Osório; Andreia Silva Evangelista; Liliana Sampaio Costa Mendes; Daniel Ferraz de Campos Mazo; Elodie Bonfim Hyppolito; Adrielly de Souza Martins; Liana Codes; Izabelle Venturini Signorelli; Geisa Perez Medina Gomide; Luciana Agoglia; Claudia Alexandra Pontes Ivantes; Valéria Ferreira de Almeida E Borges; Gabriela Perdomo Coral; Rosamar Eulira Fontes Rezende; Maria Lucia Gomes Ferraz; Debora Raquel Benedita Terrabuio; Eduardo Luiz Rachid Cançado; Claudia Alves Couto
Journal:  Can J Gastroenterol Hepatol       Date:  2021-11-10

Review 5.  The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective.

Authors:  Kevin De Muynck; Bart Vanderborght; Hans Van Vlierberghe; Lindsey Devisscher
Journal:  Cells       Date:  2021-10-30       Impact factor: 6.600

6.  Temporal Relationship of Extraintestinal Manifestations in Inflammatory Bowel Disease.

Authors:  Istvan Fedor; Eva Zold; Zsolt Barta
Journal:  J Clin Med       Date:  2021-12-20       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.